Last reviewed · How we verify
NCT06765759: PRODUR-CARDS
Prone Duration in COVID-19 ARDS
trial in COVID - 19 in 79 participants. Completed in 30 June 2024.
30 March 2024
Quick facts
| Lead sponsor | Istanbul University - Cerrahpasa |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 79 |
| Start date | 1 January 2024 |
| Primary completion | 30 March 2024 |
| Estimated completion | 30 June 2024 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- COVID - 19 — all drugs for COVID - 19 →
- Acute Respiratory Distress Syndrome (ARDS) — all drugs for Acute Respiratory Distress Syndrome (ARDS) →
Sponsor
Istanbul University - Cerrahpasa
Who can join
Adults 18 to 80, any sex, with COVID - 19 or Acute Respiratory Distress Syndrome (ARDS). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this observational study is to learn the effects of prone position duration on patient outcomes in patients with severe acute respiratory distress syndrome (ARDS) due to Coronavirus Disease - 2019 (COVID-19). The main question it aims to answer is: Does the length of prone position duration affect gas exchange in patients with severe ARDS and is there a difference between genders in this regard? The differences in gas exchange between those who have been in prone position for 16-24 hours and those who have been in prone position for 24-36 hours as part of severe ARDS treatment will be examined.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06765759
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID - 19
Currently open trials in the same condition.
- NCT07197164 — Safety and Effectiveness of a Remdesivir Treatment to Prevent Severe COVID-19 in Kidney Transplant Patients · Phase 2 · recruiting
- NCT07150871 — Impact of Covid-19 on Syphilis · active not recruiting
- NCT07204366 — Autoantibodies Against Type I Interferon in Patients Affected With Ph-negative Myeloproliferative Neoplasms (MPN-IFN Stu · active not recruiting
Other Istanbul University - Cerrahpasa trials
Trials by the same sponsor.
- NCT07588685 — Validity and Reliability of the Turkish Form of the Enjoyment of Physical Activity Scale-8 in Geriatrics With Minimal Co · not yet recruiting
- NCT07370025 — The Effect of Lullaby During Bath Time on Mother-Infant Bonding, Postpartum Depression, and Parental Self-Efficacy in In · NA · not yet recruiting
- NCT07378449 — The Effect of Hand Exercise Hoops on Labour Pain · NA · not yet recruiting
- NCT07293000 — Evaluating Two Nursing Interventions to Prevent Urinary Retention After Spinal Anesthesia · NA · not yet recruiting
- NCT07562880 — Validity and Reliability of the Exercise-Related Health Beliefs Attitude Scale in Geriatric Individuals · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06765759 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istanbul University - Cerrahpasa
- Last refreshed: 9 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06765759.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing